Anxiolytic-like property of risperidone and olanzapine as examined in multiple measures of fear in rats

Pharmacology Biochemistry and Behavior

Volumn 95, Issue 3, 2010, Pages 298-307

  Sun, Tao ^a,b   He, Wei ^b   Hu, Gang ^a   Li, Ming ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

22kHz ultrasonic vocalizations; Chlordiazepoxide; Citalopram; Conditioned avoidance response; Elevated plus maze; Haloperidol; Olanzapine; Risperidone; Startle responses; Stress induced hyperthermia

Indexed keywords

CHLORDIAZEPOXIDE; CITALOPRAM; HALOPERIDOL; OLANZAPINE; RISPERIDONE; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DEFECATION; DRUG DOSE COMPARISON; DRUG EFFICACY; FEAR; HYPERTHERMIA; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; RESPONSE TIME; STARTLE REFLEX; TASK PERFORMANCE; TRANQUILIZING ACTIVITY; VOCALIZATION; ANIMAL; COMPARATIVE STUDY; DRUG EFFECTS; PHYSIOLOGY; PSYCHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-ANXIETY AGENTS; AVOIDANCE LEARNING; BENZODIAZEPINES; FEAR; MALE; MAZE LEARNING; MODELS, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; STARTLE REACTION; VOCALIZATION, ANIMAL; REFLEX, STARTLE;

RATTUS;

EID: 77950461093     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.02.005     Document Type: Article

References (54)

1. Akwa Y., Purdy R.H., Koob G.F., Britton K.T. The amygdala mediates the anxiolytic-like effect of the neurosteroid allopregnanolone in rat. Behav Brain Res 1999, 106:119-125.
2. Bitran D., Klibansky D.A., Martin G.A. The neurosteroid pregnanolone prevents the anxiogenic-like effect of inescapable shock in the rat. Psychopharmacology (Berl) 2000, 151:31-37.
3. Blin O., Azorin J.M., Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 1996, 16:38-44.
4. Bolles R.C. Species-specific defense reactions and avoidance learning. Psychol Rev 1970, 77:32-48.
5. Bolles R.C., Grossen N.E. Function of the CS in shuttle-box avoidance learning by rats. J Comp Physiol Psychol 1970, 70:165-169.
6. Brooke N.S., Wiersgalla M., Salzman C. Atypical uses of atypical antipsychotics. Harv Rev Psychiatry 2005, 13:317-339.
7. Brot M.D., Akwa Y., Purdy R.H., Koob G.F., Britton K.T. The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with GABA(A) receptors. Eur J Pharmacol 1997, 325:1-7.
8. Butterfield M.I., Becker M.E., Connor K.M., Sutherland S., Churchill L.E., Davidson J.R. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol 2001, 16:197-203.
9. Carson W.H., Kitagawa H. Drug development for anxiety disorders: new roles for atypical antipsychotics. Psychopharmacol Bull 2004, 38:38-45.
10. Davis M. Pharmacological and anatomical analysis of fear conditioning using the fear-potentiated startle paradigm. Behav Neurosci 1986, 100:814-824.
11. Davis M., Whalen P.J. The amygdala: vigilance and emotion. Mol Psychiatry 2001, 6:13-34.
12. De Vry J., Benz U., Schreiber R., Traber J. Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. Eur J Pharmacol 1993, 249:331-339.
13. Fanselow M.S. Conditioned fear-induced opiate analgesia: a competing motivational state theory of stress analgesia. Ann N Y Acad Sci 1986, 467:40-54.
14. Fernandes C., File S.E. The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol Biochem Behav 1996, 54:31-40.
15. Frye C.A., Seliga A.M. Olanzapine's effects to reduce fear and anxiety and enhance social interactions coincide with increased progestin concentrations of ovariectomized rats. Psychoneuroendocrinology 2003, 28:657-673.
16. Godsil B.P., Quinn J.J., Fanselow M.S. Body temperature as a conditional response measure for Pavlovian fear conditioning. Learn Mem 2000, 7:353-356.
17. Griebel G., Moreau J.L., Jenck F., Misslin R., Martin J.R. Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology (Berl) 1994, 113:463-470.
18. Hamner M.B. Clozapine treatment for a veteran with comorbid psychosis and PTSD. Am J Psychiatry 1996, 153:841.
19. Hamner M.B., Faldowski R.A., Ulmer H.G., Frueh B.C., Huber M.G., Arana G.W. Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol 2003, 18:1-8.
20. Horacek J., Bubenikova-Valesova V., Kopecek M., Palenicek T., Dockery C., Mohr P., et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006, 20:389-409.
21. Ichihara K., Nabeshima T., Kameyama T. Effects of haloperidol, sulpiride and SCH 23390 on passive avoidance learning in mice. Eur J Pharmacol 1988, 151:435-442.
22. Ishida-Tokuda K., Ohno Y., Sakamoto H., Ishibashi T., Wakabayashi J., Tojima R., et al. Evaluation of perospirone (SM-9018), a novel serotonin-2 and dopamine-2 receptor antagonist, and other antipsychotics in the conditioned fear stress-induced freezing behavior model in rats. Jpn J Pharmacol 1996, 72:119-126.
23. Kamin L.J. The effects of termination of the CS and avoidance of the US on avoidance learning. J Comp Physiol Psychol 1956, 49:420-424.
24. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003, 305:625-631.
25. Karl T., Duffy L., O'Brien E., Matsumoto I., Dedova I. Behavioural effects of chronic haloperidol and risperidone treatment in rats. Behav Brain Res 2006, 171:286-294.
26. Kovacs G.L., de Wied D. Effects of amphetamine and haloperidol on avoidance behavior and exploratory activity. Eur J Pharmacol 1978, 53:103-107.
27. Le Pen G., Moreau J.L. Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropsychopharmacology 2002, 27:1-11.
28. Levis D.J., Brewer K.E. The neurotic paradox: attempts by two-factor fear theory and alternative avoidance models to resolve the issues associated with sustained avoidance responding in extinction. Handbook of contemporary learning theories 2001, 561-597. Lawrence Erlbaum Associates, Mahwah, NJ. R.R. Mowrer, S.B. Klein (Eds.).
29. Locchi F., Dall'olio R., Gandolfi O., Rimondini R. Olanzapine counteracts stress-induced anxiety-like behavior in rats. Neurosci Lett 2008, 438:146-149.
30. Majewska M.D. Steroid regulation of the GABAA receptor: ligand binding, chloride transport and behaviour. Ciba Found Symp 1990, 153:83-97. discussion-106.
31. Marx C.E., Shampine L.J., Duncan G.E., VanDoren M.J., Grobin A.C., Massing M.W., et al. Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy?. Pharmacol Biochem Behav 2006, 84:598-608.
32. Marx C.E., Shampine L.J., Khisti R.T., Trost W.T., Bradford D.W., Grobin A.C., et al. Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. Pharmacol Biochem Behav 2006, 84:609-617.
33. Marx C.E., VanDoren M.J., Duncan G.E., Lieberman J.A., Morrow A.L. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology 2003, 28:1-13.
34. Mead A, Li M. Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism. J Psychopharmacol in press.
35. Mead A., Li M., Kapur S. Clozapine and olanzapine exhibit an intrinsic anxiolytic property in two conditioned fear paradigms: contrast with haloperidol and chlordiazepoxide. Pharmacol Biochem Behav 2008, 90:551-562.
36. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog.Neuropsychopharmacol Biol Psychiatry 2003, 27:1159-1172.
37. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005, 10:79-104.
38. Monnelly E.P., Ciraulo D.A., Knapp C., Keane T. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 2003, 23:193-196.
39. Moore N.A., Rees G., Sanger G., Tye N.C. Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 1994, 5:196-202.
40. Moore N.A., Tye N.C., Axton M.S., Risius F.C. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 1992, 262:545-551.
41. Petty F., Brannan S., Casada J., Davis L.L., Gajewski V., Kramer G.L., et al. Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int Clin Psychopharmacol 2001, 16:331-337.
42. Rescorla R.A., Solomon R.L. Two-process learning theory: relationships between Pavlovian conditioning and instrumental learning. Psychol Rev 1967, 74:151-182.
43. Sanchez C. vocalisation in adult animals. A valid model of anxiety?. Eur J Pharmacol 2003, 463:133-143.
44. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 2006, 10:515-531.
45. Siemiatkowski M., Maciejak P., Sienkiewicz-Jarosz H., Czlonkowska A.I., Szyndler J., Gryczynska A., et al. Opposite effects of olanzapine and haloperidol in rat ultrasonic vocalization test. Pol J Pharmacol 2001, 53:669-673.
46. Swerdlow N.R., Bakshi V., Geyer M.A. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 1996, 279:1290-1299.
47. Thiessen D.D., Upchurch M. Haloperidol and clonidine increase, and apomorphine decreases ultrasonic vocalizations by gerbils. Psychopharmacology (Berl) 1981, 75:287-290.
48. Timmerman W., Tepper P.G., Bohus B.G., Horn A.S. The potential antipsychotic activity of the partial dopamine receptor agonist (+)N-0437. Eur J Pharmacol 1990, 181:253-260.
49. Ugale R.R., Hirani K., Morelli M., Chopde C.T. Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents. Neuropsychopharmacology 2004, 29:1597-1609.
50. Wadenberg M.L., Hicks P.B. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?. Neurosci Biobehav Rev 1999, 23:851-862.
51. Walf A.A., Frye C.A. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2007, 2:322-328.
52. Walker D.L., Davis M. The role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction. Pharmacol Biochem Behav 2002, 71:379-392.
53. Wiley J.L., Compton A.D., Porter J.H. Effects of four antipsychotics on punished responding in rats. Pharmacol Biochem Behav 1993, 45:263-267.
54. Wynn J.K., Green M.F., Sprock J., Light G.A., Widmark C., Reist C., et al. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res 2007, 95:134-142.